attacks the ciliated epithelium. By destroying the ciliated epithelium, M. hyopneumoniae impairs the defence mechanisms of the respiratory tract (mucocilliary clearance) which would normally protect against invading pathogens. Ciliary destruction by M. hyopneumoniae eventually leads to the typical clinical signs of enzootic pneumonia which are often aggravated by secondary infections. For each 10% of lung tissue affected, weight gain is reduced by 37g /day.¹

with M. hyopneumoniae has been studied in detail in several recent epidemiological surveys (see table 1). Based on sero-conversion, the time of infection can be estimated according to the following sequence of events:

against M. hyopneumoniae should meet the following criteria. It should be:

1. Early enough to allow onset of protection before relevant fi eld infection occurs,

2. Late enough to avoid interference with maternal antibodies.

Based on recent publications, vaccination at 3 to 5 weeks of age, i.e. at weaning, provides effective protection ^{9, 10, 11, 12} even when infection occurs late in the finishing period.¹¹ At 3 to 5 weeks of age maternal antibodies have largely decayed whilst pigs usually have not yet been exposed to relevant infections.

The only Mycoplasma 1-Shot Vaccine with a Depot-Adjuvant.

The unique Impran® depot-adjuvant facilitates a prolonged antigen release.^{13, 14}

In an in-vitro study, it is shown that aluminium hydroxide and oil-in-water emulsion adjuvants are characterised by a rapid release of antigen while Impran® promotes a sustained release (see figure 4).

A similar amount of antigen released by Impran® in 36 days is released by an oil-in-water emulsion in 5 hours and an aluminium hydroxide adjuvant in less than 1 hour.¹⁵

Due to it’s unique adjuvant system, Ingelvac® M.hyo has a higher viscosity than conventional Mycoplasma vaccines - but is simple and easy to use!

Despite its sustained stimulation of the immune system, Ingelvac® M.hyo leads to a rapid onset of protection, one of the the quickest of currently available M.hyo vaccines.¹⁶

Furthermore, Ingelvac® M.hyo provides improved humoral and cellular response compared to some competitor 1- and 2-shot products (see fi g 5).¹⁷

As well as a rapid onset of immunity and improved cell-mediated and humoral response, recent work confi rms that Ingelvac® M.hyo provides an extended duration of immunity – up to 34 weeks post vaccination.

prove the reliable efficacy of Ingelvac® M.hyo.

A meta analysis of 6 studies (see table 2 below) confi rms that Ingelvac® M.hyo performs at least as well, and often better than, the currently available 2-shot competitors in terms of average daily gain (ADG).¹²

1. Straw, B. et al. (1989): Estimation of the cost of pneumonia in swine herds. JAVMA, Vol 195, No. 12, p 1702 -1706

2. Pabst, T. et al. (2004): Diagnostic of Enzootic Pneumonia in vaccinated herds endemically infected with Mycoplasma hyopneumoniae. Proceedings 18th IPVS congress, Hamburg 2004.

3. Leon, E. A. et al. (2001): Seroepidemiology of Mycoplasma hyopneumoniae in pigs from farrow-to-fi nish farms. Vet. Mic., 78, 331-341

4. Andreasen, M. et al. (2000): A longitudinal study of serological patterns of respiratory infections in nine infected Danish swine herds. Prev. Vet. Med., 45, p 221-235

5. Ohlinger, V. et al. (2000): The use of polymerase chain reaction (PCR) and serology (ELISA) to determine Mycoplasma hyopneumoniae infection in German pig herds. Proceedings of 16th IPVS Congress, Melbourne, 17-20 September 2000, p 453

6. Ohlinger, V. et al. (2002): Key sucess factors involved in the control of respiratory diseases in swine. Swine respiratory health symposium - PRRS / M. hyo, March 15. -17., 2002, Monte Carlo, Monaco

7. Vicca, J. et al. (2001): Patterns of Mycoplasma hyopneumoniae infection in clinically and subclinically infected farrow – to fi nish pig herds with good or poor management and housing conditions. Gent University, 2001

8. Yagihashi, T. et al. (1993): Seroepidemiology of Mycoplasmal pneumonia of swine in Japan as surveyed by an enzyme-linked immunosorbent assay. Vet. Microbiol., 34, p 155-166

9. Pabst, T. et große Beilage, E. (2004): The effi cacy of single-dose Ingelvac® M.hyo in endemically infected herds. Proceedings 18th IPVS congress, Hamburg 2004.

10. Marco, et al. Field effi cacy of a single dose Mycoplasma hyopneumoniae vaccine in farrow to fi nish operations. Proceedings of the 18th IPVS congress, Hamburg 2004

11. Genzow, M. et al. (2002): Field effi cacy study of Ingelvac® M. hyo administerd to 3 week old piglets in a M. hyo infected herd in Germany. Swine respiratory health symposium - PRRS / M. hyo, March 15. -17., 2002, Monte Carlo, Monaco, submitted for publication

12. Kolb, J. et al. (2004): Summary of fi eld trials comparing Ingelvac® M.hyo vs. conventional M.hyo vaccines. Accepted for publication

13. Dupuis, L. (2002): Control of vaccine behaviour. Pig Progress, 18, 26-276.

14. Herbach, N. (2005): Adjuvants designed for Mycoplasma hyopneumoniae vaccines. International Pig topics vol 20, No. 5.

15. Internal report (Seppic 2002)

16. Roof, M. et Kolb, J. (2004): Rapid onset of protection against Mycoplasma hyopneumoniae. Proceedings 18th IPVS congress, Hamburg 2004.

17. Roof, M. B. et al. (2001): Evaluation of the immune response and effi cacy of 1 and 2 dose commercial Mycoplasma hyopneumoniae bacterins. Proceedings of 32nd Annual Meeting AASV, Nashville, 24 -27. February 2001, p 163 -167

18. Genzow, M. et al (2005): New evidence for extended duration of protection of Ingelvac M.hyo. Internal report.

19. Marco, E. et al. (2003): An update on Mycoplasma vaccines. Int. Pig Topics, Vol 18, No. 3, P 11-13.